Skip to main content

Puma Biotechnology, Inc.

corporate_fare Company Profile

Puma Biotechnology, Inc.

PBYI·NASDAQ·Life Sciences·CIK 0001401667

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products to improve cancer care and patient treatment outcomes. The company currently commercializes NERLYNX, an oral form of neratinib, which is used to treat certain HER2-positive breast cancers. Puma Biotechnology has also in-licensed alisertib, for which it is responsible for global development and commercialization. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A, designed to disrupt cell division and lead to the death of rapidly growing tumor cells that rely on Aurora Kinase A. Before Puma Biotechnology licensed alisertib from a Takeda Pharmaceutical Company Limited subsidiary, it was tested in over 1,300 patients across 22 company-sponsored trials, creating a large clinical safety database. Based on this data, Puma Biotechnology believes alisertib could be used to treat various cancer types, including hormone receptor-positive breast cancer, triple negative breast cancer, and small cell lung cancer. The company plans to initially develop alisertib for small cell lung cancer and hormone receptor-positive breast cancer.

Puma Biotechnology, Inc. (NASDAQ:PBYI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for PBYI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for PBYI spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Puma 10-Q Discloses New Material Weakness Tied to ERP Rollout; Q3 Net Income Falls to $6.0M
  • Puma Q3 Net Income Falls to $6.0M; Full-Year Profit Outlook Raised to $20-22M
  • Puma Biotech Beats Q2 Estimates, Retires All Debt, but Loses Key Patent Appeal
  • Puma Biotech Raises 2026 Outlook as NERLYNX Demand Drives Q2 Beat
  • Puma Biotechnology Beats Q2 Estimates and Lifts Full-Year Outlook on Robust NERLYNX Demand

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$228.37M
Net Income
$31.11M
Diluted EPS
$0.61
Op. Cash Flow
$41.8M
Free Cash Flow
$41.73M
Gross Profit
$170.21M
Operating Income
$37.3M
Cash & Equivalents
$29.64M
Total Debt
$22.52M
Debt / Equity
0.17×
Net Margin
13.6%
Shares Outstanding
50.41M sh
Source: 10-K · filed 2026-02-26 · accession 0001437749-26-005891

Short Interest & Short Volume

11.51 days to cover

FINRA reported short interest of 4,298,038 shares in PBYI as of the October 30, 2026 settlement, a 5.3% decrease from the prior period — about 11.5 days to cover at its recent average daily volume. On November 20, 2026, 41.1% of PBYI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,298,038 shares as of October 30, 2026
Change vs prior period▼ 5.3%
Days to cover11.51 at avg daily volume of 373,513
Daily short volume (FINRA facilities)41.1% of 262,295 shares on November 20, 2026
5-day average short volume49.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$7.05
52-week range · as of 2026-11-09 $4.58 – $11.5
Market cap
$364.47M
Volume
861.2K (1.8× avg)
3-mo avg 466.9K
Live data · 2026-11-22 01:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PBYI - Latest Insights

PBYI
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.40
Real-time Price: $7.05 info
Change: -$1.34 (-16%) info
Market Cap: $364.473M info
PBYI
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.77
Real-time Price: $7.05 info
Change: -$2.72 (-28%) info
Market Cap: $364.473M info
PBYI
Aug 06, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.12
Real-time Price: $7.05 info
Change: -$1.07 (-13%) info
Market Cap: $364.473M info
PBYI
Aug 06, 2026, 4:35 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $8.12
Real-time Price: $7.05 info
Change: -$1.07 (-13%) info
Market Cap: $364.473M info
PBYI
Aug 06, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.12
Real-time Price: $7.05 info
Change: -$1.07 (-13%) info
Market Cap: $364.473M info
PBYI
Jun 16, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.17
Real-time Price: $7.05 info
Change: -$0.120 (-2%) info
Market Cap: $364.473M info
PBYI
May 07, 2026, 5:03 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $7.29
Real-time Price: $7.05 info
Change: -$0.237 (-3%) info
Market Cap: $364.473M info
PBYI
May 07, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.21
Real-time Price: $7.05 info
Change: -$0.1568 (-2%) info
Market Cap: $364.473M info
PBYI
Apr 28, 2026, 4:17 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $7.54
Real-time Price: $7.05 info
Change: -$0.490 (-6%) info
Market Cap: $364.473M info
PBYI
Apr 28, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.54
Real-time Price: $7.05 info
Change: -$0.490 (-6%) info
Market Cap: $364.473M info
PBYI
Apr 07, 2026, 5:11 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $7.05 info
Change: +$0.080 (+1%) info
Market Cap: $364.473M info
PBYI
Feb 26, 2026, 4:41 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $7.20
Real-time Price: $7.05 info
Change: -$0.150 (-2%) info
Market Cap: $364.473M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets